<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               7	DRUG INTERACTIONS<BR>               <BR>                  In healthy subjects who were administered peginterferon alfa-2b subcutaneously at 1 mcg/kg once weekly for four weeks with probe drugs of metabolic enzymes administered before the first dose and after the fourth dose, a measure of CYP2C9 activity increased to 125% of baseline, whereas a measure of CYP2D6 activity decreased to 51% of baseline [see Clinical Pharmacology (12.3)].<BR>                  When administering SYLATRON with medications metabolized by CYP2C9 or CYP2D6, the therapeutic effect of these drugs may be altered.<BR>                  The effects of pegylated interferon alfa-2b on the pharmacokinetics of drugs metabolized by cytochrome P-450 enzymes have not been studied at the higher clinical doses for patients with melanoma (3 mcg/kg/week and 6 mcg/kg/week).<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Drug metabolized by cytochrome P-450 (CYP) enzymes: Monitor closely when used in combination with drugs metabolized by CYP2C9 or CYP2D6. (7)<BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>